Hepatectomy for metachronous colorectal liver metastases following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a report of three cases.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chemotherapy, Cancer, Regional Perfusion
/ methods
Colorectal Neoplasms
/ complications
Combined Modality Therapy
Cytoreduction Surgical Procedures
/ methods
Female
Hepatectomy
Humans
Hyperthermia, Induced
/ methods
Liver Neoplasms
/ complications
Male
Middle Aged
Neoplasms, Second Primary
/ complications
Peritoneal Neoplasms
/ complications
Prognosis
Colorectal cancer
Cytoreductive surgery
Hepatectomy
Hyperthermic intraperitoneal chemotherapy
Liver metastases
Multi-modality treatment
Peritoneal metastases
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
13 Jun 2019
13 Jun 2019
Historique:
received:
05
03
2019
accepted:
05
06
2019
entrez:
15
6
2019
pubmed:
15
6
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis (PM) from colorectal cancer (CRC) has been reported to substantially improve the prognosis and the quality of life of patients in comparison to systemic chemotherapy or palliative approaches. This study aimed to demonstrate the safety and feasibility of hepatectomy for metachronous liver metastases from CRC following CRS and HIPEC for PM on the basis of three case reports. We describe three cases involving patients who underwent hepatectomy for metachronous liver metastases from CRC after CRS and HIPEC for PM. All patients underwent CRS and HIPEC after primary tumor resection, and hepatectomy was performed for the metachronous liver metastases after CRS and HIPEC. The hepatectomy procedures for cases 1, 2, and 3 were left hemihepatectomy and partial resection of S5, posterior sectionectomy, and left-lateral sectionectomy and partial resection of S5 and S8, respectively. Although adhesion of surrounding organs to the liver surface was observed on a broad level, dissections and hepatectomy could be performed safely. No recurrence was detected in cases 1 and 2 after hepatectomy. In case 3, liver metastases were detected from the time of the initial diagnosis of the primary tumor, and complete remission was achieved once with systemic chemotherapy. Although we performed hepatectomy for the recurrence of liver metastases after complete remission, early re-recurrence was observed after hepatectomy. Hepatectomy for metachronous liver metastases after CRS and HIPEC for PM could be a multi-modality treatment option for CRC recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis (PM) from colorectal cancer (CRC) has been reported to substantially improve the prognosis and the quality of life of patients in comparison to systemic chemotherapy or palliative approaches. This study aimed to demonstrate the safety and feasibility of hepatectomy for metachronous liver metastases from CRC following CRS and HIPEC for PM on the basis of three case reports.
CASE PRESENTATION
METHODS
We describe three cases involving patients who underwent hepatectomy for metachronous liver metastases from CRC after CRS and HIPEC for PM. All patients underwent CRS and HIPEC after primary tumor resection, and hepatectomy was performed for the metachronous liver metastases after CRS and HIPEC. The hepatectomy procedures for cases 1, 2, and 3 were left hemihepatectomy and partial resection of S5, posterior sectionectomy, and left-lateral sectionectomy and partial resection of S5 and S8, respectively. Although adhesion of surrounding organs to the liver surface was observed on a broad level, dissections and hepatectomy could be performed safely. No recurrence was detected in cases 1 and 2 after hepatectomy. In case 3, liver metastases were detected from the time of the initial diagnosis of the primary tumor, and complete remission was achieved once with systemic chemotherapy. Although we performed hepatectomy for the recurrence of liver metastases after complete remission, early re-recurrence was observed after hepatectomy.
CONCLUSIONS
CONCLUSIONS
Hepatectomy for metachronous liver metastases after CRS and HIPEC for PM could be a multi-modality treatment option for CRC recurrence.
Identifiants
pubmed: 31196097
doi: 10.1186/s12957-019-1646-0
pii: 10.1186/s12957-019-1646-0
pmc: PMC6567639
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
99Références
Cancer. 2000 Jan 15;88(2):358-63
pubmed: 10640968
Ann Surg Oncol. 2001 May;8(4):347-53
pubmed: 11352309
Hum Reprod Update. 2001 Nov-Dec;7(6):556-66
pubmed: 11727864
Br J Surg. 2002 Dec;89(12):1545-50
pubmed: 12445064
J Clin Oncol. 2003 Oct 15;21(20):3737-43
pubmed: 14551293
Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7
pubmed: 15166961
J Clin Oncol. 2004 Aug 15;22(16):3284-92
pubmed: 15310771
J Hepatobiliary Pancreat Surg. 2005;12(5):351-5
pubmed: 16258801
Ann Surg. 2006 Feb;243(2):212-22
pubmed: 16432354
Ann Surg. 2007 Apr;245(4):597-603
pubmed: 17414609
Ann Surg Oncol. 2008 Sep;15(9):2426-32
pubmed: 18521686
Ann Surg. 2008 Nov;248(5):829-35
pubmed: 18948811
J Clin Oncol. 2009 Feb 10;27(5):681-5
pubmed: 19103728
J Clin Oncol. 2010 Jan 1;28(1):63-8
pubmed: 19917863
Oncology. 2010;78(3-4):237-48
pubmed: 20523084
Eur J Surg Oncol. 2011 Feb;37(2):148-54
pubmed: 21093205
Eur J Surg Oncol. 2012 Jun;38(6):509-15
pubmed: 22475555
Ann Surg. 2013 Jul;258(1):116-21
pubmed: 23207243
Int J Clin Oncol. 2014 Feb;19(1):98-105
pubmed: 23239055
Langenbecks Arch Surg. 2013 Jun;398(5):745-9
pubmed: 23456355
World J Gastroenterol. 2014 Oct 14;20(38):14018-32
pubmed: 25320542
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
World J Gastroenterol. 2016 Dec 14;22(46):10249-10253
pubmed: 28028374
Ann Surg Oncol. 2018 Jan;25(1):173-178
pubmed: 29063295
Cancer Res. 1980 Feb;40(2):256-60
pubmed: 6766084
World J Surg. 1995 Mar-Apr;19(2):235-40
pubmed: 7754629
Ann Surg. 1995 Jan;221(1):29-42
pubmed: 7826158
Cancer Treat Res. 1996;81:149-68
pubmed: 8834582
Cancer Treat Res. 1996;82:359-74
pubmed: 8849962